- Company
- KDA finally agrees on SGLT2 inhibitor benefits
- by Eo, Yun-Ho Apr 14, 2020 06:15am
- The Korean Diabetes Association (KDA) has finally reached an agreement on expanding reimbursement on sodium-glucose transport protein 2 (SGLT2) inhibitor combination therapy. KDA has submitted a statement to the Korean government regarding the needs of expanded coverage on SGLT2 inhibitor plus off-label diabetes treatments, including dipe
- Policy
- Exemption of some in vivo tests when developing COVID-19
- by Lee, Tak-Sun Apr 14, 2020 06:12am
- The MFDS decided to exempt in vivo tests on some of the formulations for rapid clinical entry of COVID-19 treatments. In order to enter the clinical trial, in vitro and in vivo studies should be completed and reviewed, but in some formulations, such as antiviral drugs, in vivo studies can be replaced with existing test results. Accordin
- Company
- KPBMA “Exempt transferred originals from pricing reduction"
- by Eo, Yun-Ho Apr 14, 2020 06:12am
- All of pharmaceutical industry is responding against the risk in pricing reduction on original drugs transferred due to a split-off. Pharmaceutical industry sources reported, Korea Pharmaceutical and Bio-pharma Manufacturers Association (KPBMA) plans to deliver an official statement to the health authority demanding the government to exem
- Policy
- Saxenda's upgraded injection (once a week) will be imminent
- by Lee, Tak-Sun Apr 14, 2020 06:11am
- Saxenda's upgraded version of the drug, which is causing a sensation in the domestic obesity treatment market, is predicting clinical trials in Korea, attracting attention. It was Ozempic (Semaglutide), which improved the convenience of administration by injection once a week. The MFDS approved IND for Semaglutide applied by Novonordisk
- Policy
- The government, cuts health insurance premiums by 50%
- by Kim, Jung-Ju Apr 14, 2020 06:11am
- The government has decided to temporarily cut down some health insurance premiums to alleviate the economic damage of low-income and small business owners. The Ministry of Health and Welfare (Minister Park Neung-hoo) announced on the 10th that from March to May, it would reduce (30-50%) the health insurance premiums of the bottom 50% in s
- Policy
- Chong Kun Dang’s capsuled low-dose Xarelto generic approved
- by Lee, Tak-Sun Apr 14, 2020 06:11am
- Chong Kun Dang’s generic version of Bayer’s anticoagulant Xarelto (rivaroxaban) tablet was approved as a first capsule form in Korea. The 2.5 mg low-dose capsule would be able to evade Hanmi Pharmaceutical and SK Chemical’s preferential sales rights on their generic products with the change in administration form. On Apr. 9, Minist
- Policy
- Controversy concludes about COVID-19 & Safety of HTN drugs
- by Lee, in-bok Apr 13, 2020 06:13am
- It is expected that clinical studies will begin in Korea to determine the association between COVID-19 and angiotensin converting enzyme (ACE) -based hypertensive drugs. It is a willingness to uncover whether it can be a threat to domestic hypertensive patients in terms of controversial issues worldwide. It was confirmed that the publ
- Policy
- President Moon “Expediting COVID-19 treatment approval”
- by Lee, Jeong-Hwan Apr 13, 2020 06:13am
- Amid COVID-19 pandemic, President Moon Jae-in of South Korea has expressed his expectation for Korean-made treatment and vaccine to save the humanity. President Moon personally emphasized the government support for the COVID-19 treatment vaccine through R&D investment and expedited approval process. At a meeting convened on Apr. 9 fo
- Policy
- 161 items, subject to monitoring for Price-Volume agreement
- by Lee, Hye-Kyung Apr 13, 2020 06:12am
- AstraZeneca Korea's Tagrisso 40mg/80 mg (Osimatinib Mesylate) were added to the monitoring target for the price-volume agreement negotiation system in the second quarter of this year. Celgine's Pomalyst (Pomalidomide) 1·2·3·4 mg, Roche Korea's Tecentriq (Atezolizumab), and Jansen Korea's Sylvant (Siltuximab) 100·400 mg are also subject
- Policy
- Salt-altering drugs for Pristiq ER got generic exclusivity
- by Lee, Tak-Sun Apr 13, 2020 06:12am
- Pfizer's first generic drug for anti-depressant drug Pristiq ER (Desvenlafaxine) was also approved as generic exclusivity. Accordingly, four generics of Whan In, Myungin, Nexpharm Korea, Hallim, will be able to monopolize in the same ingredient formulation market until January 8, next year. On the 8th, the MFDS approved Whan In’s Defax
